The DOI matches its Crossref record; 889 of the 893 references it cites were found in a registry or an index, and 4 are not checked yet.
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
Open accessAbstract
The individual reviewers' relationships with industry information is available in Appendix 2.This document was approved for publication by the governing bodies of the ASA and the AHA.It was reviewed for evidence-based integrity
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with CKM stage 1 due to overweight and obesity are at increased risk for developing metabolic risk factors and CKD compared with those who have a normal weight without risk factors (CKM stage 0).5,6,41”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in the absence of these metabolic risk factors, excess weight is associated with increased cardiovascular risk, particularly for HF.6,42”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is a particular focus on preventing the development of excess and dysfunctional adipose tissue because the emergence of metabolic risk factors from youth and young adulthood into middle age is primarily related to weight gain with aging.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For adults with overweight or obesity who have significant barriers to participating in multicomponent behavioral weight loss interventions, self-directed digital health solutions can be beneficial to promote weight loss for CKM syndrome risk reduction.5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among patients with CKM stage 1 to 3 and obesity without an adequate weight loss response to lifestyle modification, with or without the use of adjunctive obesity pharmacotherapies, MBS can be beneficial to facilitate weight loss and to mitigate CKM syndrome progression.1–8”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS has efficacy among individuals with a BMI ≥35 kg/m2 regardless of the presence of comorbidities and can be beneficial in patients with T2D with a threshold BMI of 30 kg/m2.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glycemia consistently improves with use of these agents, with some evidence for preventing progression to diabetes in those with insulin resistance.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS has efficacy among individuals with a BMI ≥35 kg/m2 regardless of the presence of comorbidities and can be beneficial in patients with T2D with a threshold BMI of 30 kg/m2.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Counseling on dietary or combined dietary and exercise modifications effectively facilitates weight loss in postpartum women with GDM.6,19–21”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RASi provide BP control and kidney and cardiovascular protection6 and are therefore preferred in patients with CKD and albuminuria.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials and meta-analyses of SGLT2i in patients with CKD and T2D or CKD and UACR ≥200 mg/g without T2D have shown a significant reduction in risks of losing kidney function, kidney failure, cardiovascular death, and HF hospitalization when compared with placebo.5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of subclinical atherosclerosis (eg, elevated CAC) is associated with an increased cardiovascular risk among those with CKM risk factors (eg, diabetes, CKD).5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A heart-healthy diet and regular physical activity remain the cornerstones of therapy in patients with T2D and ASCVD, with demonstrated benefits for CKM risk profiles.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, habitual physical activity, including activities that reduce sedentary time, aerobic physical activity, and resistance training, are associated with improvements in several CKM risk factors (HbA1c, waist circumference, fat percentage, BP) and mortality.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS is associated with a lower risk of incident major adverse liver outcomes and MACE in large cohort studies.6,24,25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a 60% increased risk of stroke recurrence.35”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Standard stroke care includes medical treatment, routine stroke therapy, and rehabilitative exercises, as outlined in the basic guidelines [35,36].”
From Smartphone-Based Speech Therapy for Poststroke Dysarthria: Pilot Randomized Controlled Trial Evaluating Efficacy and Feasibility (2024) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, current guidelines recommend short-term dual antiplatelet therapy after high-risk transient ischemic attack and minor stroke (198).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [198]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, owing to the chronicity of obesity and multiple compensatory changes in metabolism, hunger, and satiety promoting weight recidivism,6 frequent and long-term engagement and behavioral support for lifestyle modification are needed for optimal effectiveness.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, as per clinical guidelines, persistently elevated triglycerides are considered a risk enhancer for ASCVD.2,4–6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“CAC assessment improves prediction of ASCVD4,5 and selection of patients for treatment with aggressive ASCVD risk factor modification (ie, statin therapy).6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“CorCal (Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of CAC Screening, in Preventing Future MACE)6 randomized 601 primary prevention patients to CAC (n=302) or risk calculator guidance (n=299) for primary prevention; the CAC arm had a greater reclassification of risk compared with the group using a risk calculator.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At 1 year, statin adherence was superior, low-density lipoprotein cholesterol (LDL-C) levels were lower, and estimated costs were similar or reduced in the CAC arm.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At 1 year, statin adherence was superior, low-density lipoprotein cholesterol (LDL-C) levels were lower, and estimated costs were similar or reduced in the CAC arm.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At 1 year, statin adherence was superior, low-density lipoprotein cholesterol (LDL-C) levels were lower, and estimated costs were similar or reduced in the CAC arm.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Once obesity is established, multiple compensatory mechanisms impacting metabolism, hunger, and satiety are triggered in the setting of intentional weight loss, which commonly result in weight regain.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In EMPA-Kidney, the risk reduction for the primary outcome (a composite of progression of kidney disease or death from cardiovascular causes) with empagliflozin compared with placebo was larger among patients with higher UACR (UACR ≥30–300: HR, 0.91; 95% CI, 0.65–1.26 versus UACR ≥300: HR, 0.67; 95% CI, 0.58–0.78).6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, the rate of eGFR decline after the initial decrease was slower in the empagliflozin group than in the placebo group in all key subgroups, including in the subgroup of patients with a UACR <30 mg/g.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Simulation studies suggest that combinations of CKM therapies may have additive benefits for heart and kidney protection.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the SELECT trial,6 17 604 participants with BMI ≥27 kg/m2 and established ASCVD (prior MI, stroke, or symptomatic PAD), and without T2D, end-stage kidney disease, or dialysis, were enrolled. The trial demonstrated a 20% reduction in risk of the composite primary endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke for those treated with semaglutide (2.4 mg) as compared with placebo”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A single-arm 15-week pragmatic weight management program (weekly consultations with exercise specialists, dietitians, and behavioral specialists), achieved a mean weight loss of 8.1 kg (−6.7%) for patients with obesity-related HFpEF.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among patients with HFrEF, RASi improves both HF outcomes and risk for worsening kidney disease in several clinical trials.1–8,28”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A directionally similar reduction in risk of the cardiovascular outcome (cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization for HF) was observed in a subgroup with CKD G4 in the FIDELITY meta-analysis of finerenone in diabetic patients, but this was nonsignificant and requires further investigation.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Metabolic and bariatric surgery causes remission of MASLD, even in advanced stages.6,24,25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hyperkalemia was more frequent in those with CKD G4 treated with finerenone.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Abdominal adiposity is one of the strongest VTE risk factors.3,5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“Accordingly, many guidelines now recommend the addition of GLP-1RAs to ongoing antihyperglycemic regimens to lower the risk of stroke in type 2 diabetes.”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [7]
In the citing paper
“the American Heart Association/American Stroke Association guideline suggests GLP-1RAs as second-line to metformin regardless of baseline HbA1c in individuals with established atherosclerotic CVD to avoid further vascular events 7”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [7]
In the citing paper
“In the same vein, the 2020 Canadian Stroke Best Practices update for secondary prevention of stroke, 8 2021 Spanish Society of Neurology consensus statement, 9 2021 American Heart Association/American Stroke Association Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack, 7 and the Diabetes, Cardiorenal, and Metabolic Diseases Multispecialty Task Force 55”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Albay, C. E. Q., Leyson, F. G. D., & Cheng, F. C. (2020) · BMC Neurology · doi:10.1186/s12883-020-01808-y · Cited by 22
Retracted(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,350
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Research works printed but not linked: 11
- 10.1148/radiol.10100804 · DOI
- 10.1001/jama.1988.03720070025028 · DOI
- 10.1161/JAHA.117.00785 · DOI
- Inzucchi, SE, Docherty, K, Kober, L, Kosiborod, MN, Martinez, F. Effect of dapagliflozin on the incidence of diabetes: a prespecified exploratory analysis from DAPA-HF. Paper presented at: American Diabetes Association 80th Scientific Sessions; 2020; virtual.
- 10.1161/JAHA.116.00472 · DOI
- 10.1056/NEJMoa1910355 · DOI
- 10.1136/bmj.324.7329.7 · DOI
- 10.1182/blood.V63.1.162.162 · DOI
- 10.1043/0003-9985(2002)126<0182:AFIAHI>2.0.CO;2 · DOI
- Ubogu, EE, Zaidat, OO. Vertebrobasilar dolichoectasia diagnosed by magnetic resonance angiography and risk of stroke and death: a cohort study. J Neurol Neurosurg Psychiatry. 2004;75:22–26.
- Lawrence, K, Keleher, T. Structural Racism. Paper presented at: Race and Public Policy Conference; November 11–13, 2004; Berkeley, CA.
Cited by
Sorted by citations
Items 601–700 of 1,000
Yu, H., Li, Y., Feng, Y., Zhang, L., Yao, Z., Liu, Z., Gao, W., Chen, Y., & Xie, S. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.823876 · Cited by 11
The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke
Tsankof, A., & Τζιόμαλος, Κ. (2021) · Diseases · doi:10.3390/diseases10010003 · Cited by 11
Kefer, J., Carbonez, K., Piérard, S., Mouthuy, F.-P., Peeters, A. P., Hermans, C. R. J. R., Lambert, C., DeMeester, C., Sluysmans, T., & Pasquet, A. (2022) · Journal of Interventional Cardiology · doi:10.1155/2022/6559447 · Cited by 11
Cerebrovascular Manifestations of SARS-CoV-2: A Comprehensive Review
Stefanou, Ε., Karvelas, N., Bennett, S., & Kole, C. (2023) · Current Treatment Options in Neurology · doi:10.1007/s11940-023-00747-6 · Cited by 12
A step-by-step guide for the diagnosis and management of hyponatraemia in patients with stroke
Barkas, F., Anastasiou, G., Liamis, G. L., & Milionis, H. J. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231163806 · Cited by 13
Boriani, G., Auricchio, A., Botto, G. L., Joseph, J., Roberts, G. J., Grammatico, A., Nabutovsky, Y., & Piccini, J. P. (2023) · EP Europace · doi:10.1093/europace/euad212 · Cited by 11
McCabe, J. J., Evans, N. R., Gorey, S., Bhakta, S., Rudd, J. H. F., & Kelly, P. J. (2023) · Cells · doi:10.3390/cells12162073 · Cited by 12
Evola, S., Camarda, E. A., Triolo, O. F., Adorno, D., D’Agostino, A., Novo, G., & Onorato, E. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185788 · Cited by 11
Mediation analysis of urinary metals and stroke risk by inflammatory markers
Zheng, L., Jing, X., Zhang, X., Zhong, C., Qiu, D., Yan, Q., & Gao, Z. (2023) · Chemosphere · doi:10.1016/j.chemosphere.2023.140084 · Cited by 11
Jiang, J., Hong, Y., Li, W., Wang, A., Jiang, S., Jiang, T., Wang, Y., Wang, L., Yang, S., Ren, Q., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230577 · Cited by 11
Li, Z., Gong, P., Zhang, M.-B., Li, C., Xiao, P.-L., Yu, M., Wang, X.-Z., An, L., Bi, F., Song, X., et al. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110807 · Cited by 11
Effectiveness of statins on outcomes of patients with Embolic Stroke of Undetermined Source (ESUS)
Vitturi, B. K., & Gagliardi, R. J. (2023) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2023.107469 · Cited by 11
Patel, J. B., & Bhaskar, S. M. M. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110458 · Cited by 14
Little, S. B., Sarma, A., Bajaj, M., Pruthi, S., Reddy, K. M., Reisner, A., Philbrook, B. L., & Jordan, L. C. (2023) · Radiographics · doi:10.1148/rg.230107 · Cited by 11
Qian, Y., Tan, J.-Y. B., Wang, T., Bressington, D. T., Zhou, H.-J., Li, M., & Liu, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04959-5 · Cited by 13
Campello, E., Bucciarelli, P., Catalani, F., Erba, N., Squizzato, A., Poli, D., & Scientific Reviewer Committee (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2325-5658 · Cited by 13
Ringer, A. J., Hanel, R. A., Baig, A. A., Siddiqui, A. H., Lopes, D. K., Barros, G., Bass, D. I., Levitt, M. R., Young, C. C., Naylor, R. M., et al. (2024) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2024-021977 · Cited by 11
Oe, M., Fujihara, K., Yamada, M. H., OSAWA, T., Kitazawa, M., Matsubayashi, Y., Sato, T., Yaguchi, Y., Iwanaga, M., Seida, H., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01367-7 · Cited by 10
High prevalence of obstructive sleep apnea syndrome in Spain’s Stroke Belt
Domínguez-Mayoral, A., Sánchez-Gómez, J., Guerrero, P., Ferrer, M., Gutiérrez, C. A., Aguilar, M., Rosón, N. F., Benítez, J. M., Pérez-Sánchez, S., Gamero-García, M. Á., et al. (2021) · Journal of International Medical Research · doi:10.1177/03000605211053090 · Cited by 11
Brusca, S. B., Caughron, H., Njoroge, J. N., Cheng, R., O’Brien, C., & Barnett, C. F. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000967 · Cited by 11
The Applicability of Thromboelastography in Acute Ischemic Stroke: A Literature Review
Pîrlog, B. O., & Grotta, J. C. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1753529 · Cited by 11
Barriuso, I., Worner, F., & Vilahur, G. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9110397 · Cited by 11
Big Data in Stroke: How to Use Big Data to Make the Next Management Decision
Liu, Y., Luo, Y., & Naidech, A. M. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01358-4 · Cited by 13
Acute Treatment of Disabling and Nondisabling Minor Ischemic Stroke: Expert Guidance for Clinicians
Santis, F. D., Foschi, M., D’Anna, L., Coutts, S. B., Fischer, U., Khatri, P., Nasreldein, A., Pontes‐Neto, O. M., Nguyen, T. N., Sandset, E. C., et al. (2025) · Stroke · doi:10.1161/strokeaha.125.053504 · Cited by 10
Self-citationHeo, J., Lee, H., Lee, I. H., Nam, H. S., & Kim, Y. D. (2023) · Journal of Stroke · doi:10.5853/jos.2022.02068 · Cited by 9
Management of Stroke in Patients With Chronic Liver Disease: A Practical Review
Parikh, N. S., Basu, E., Hwang, M. J., Rosenblatt, R. E., VanWagner, L. B., Lim, H. I., Murthy, S. B., & Kamel, H. (2023) · Stroke · doi:10.1161/strokeaha.123.043011 · Cited by 11
Self-citationStatin Treatment on Cardiovascular Risk After Retinal Artery Occlusion: A Historical Cohort Study
Yoo, J., Jeon, J., Shin, J. Y., Baik, M., & Kim, J. (2023) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-023-00143-y · Cited by 10
Low-density lipoprotein cholesterol, statin therapy, and cerebral microbleeds: The CIRCLE study
Zhao, Y., Zhou, Y., Zhou, H., Gong, X., Luo, Z., Li, J., Sun, J., Lou, M., & Yan, S. (2023) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103502 · Cited by 10
Zhou, T., de Havenon, A., Sheth, K. N., & Ross, J. S. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030869 · Cited by 10
Meng, X., Wang, A., Tian, X., Johnston, S. C., Li, H., Bath, P. M., Xu, Q., Zhang, Y., Xie, X., Jing, J., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000207809 · Cited by 10
Zhang, D., Jia, N., Hu, Z., Keqing, Z., Chenxi, S., Chunying, S., Chen, C.-S., Chen, W., Hu, Y., & Ruan, Z. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112374 · Cited by 10
Safouris, A., Psychogios, K., Palaiodimou, L., Orosz, P., Magoufis, G. L., Kargiotis, O., Theodorou, A., Karapanayiotides, T., Spiliοpoulos, S., Nardai, S., et al. (2024) · Journal of Stroke · doi:10.5853/jos.2023.01578 · Cited by 10
Self-citationLDL-C Levels and Bleeding Risk in Patients Taking DAPT After Minor Ischemic Stroke or TIA
Cheng, A., Xue, J., Wang, A., Xu, Q., Feng, Z., Lin, J., Li, H., Meng, X., Xu, J., & Wang, Y. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.0086 · Cited by 10
Kang, S. J., Tae, C. H., Bang, C. S., Shin, C. M., Jeong, Y., Choi, M., Hwang, J. H., Saito, Y., Chiu, P. W. Y., Rerknimitr, R., et al. (2024) · Clinical Endoscopy · doi:10.5946/ce.2024.002 · Cited by 10
Cancer and arterial thrombosis: therapeutic options
Cheong, M. A., & Leader, A. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102393 · Cited by 10
Huang, L., Zhang, Y., Liu, Y.-N., Liang, Z., Chen, J., Wang, B., Yin, Q.-L., Wang, P., Wang, W., & Qi, S.-H. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00014 · Cited by 10
A systematic review and meta-analysis of acupuncture in aspiration caused by post-stroke dysphagia
Li, H., Li, J., Wang, X., & Zhang, Z. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1305056 · Cited by 10
Fan, H., Wang, Y., Zhang, K., Liu, T., Li, X., Li, Y., Li, Y., Li, J., Ren, J. L., Liu, Y., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035337 · Cited by 10
Adult Moyamoya disease and moyamoya syndrome: what’s new?
Uchiyama, S., & Fujimura, M. (2024) · Cerebrovascular Diseases Extra · doi:10.1159/000540254 · Cited by 10
Kim, D. Y., Park, T. H., Cho, Y., Park, J., Lee, K. B., Lee, M., Lee, J., Bae, S. Y., Hong, D. Y., Jung, H., et al. (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e278 · Cited by 10
Risk factors and clinical significance of post‐stroke incident ischemic lesions
Fang, R., Duering, M., Bode, F. J., Stösser, S., Meißner, J. N., Hermann, P., Liman, T., Nolte, C. H., Kerti, L., Ikenberg, B. D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14274 · Cited by 10
Silbert, L. C. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001508 · Cited by 11
Lolekha, P., Khovidhunkit, W., Deerochanawong, C., Thongtang, N., Boonyasirinant, T., Rattarasarn, C., Chutinet, A., Ophascharoensuk, V., Somlaw, N., Sitthisook, S., et al. (2024) · Asian Biomedicine · doi:10.2478/abm-2024-0033 · Cited by 13
Poor Olfaction and Risk of Stroke in Older Adults: The Atherosclerosis Risk in Communities Study
Chamberlin, K. W., Li, C., Kucharska‐Newton, A., Luo, Z., Reeves, M. J., Shrestha, S., Pinto, J. M., Deal, J. A., Kamath, V. J., Palta, P., et al. (2025) · Stroke · doi:10.1161/strokeaha.124.048713 · Cited by 10
Kim, K., Kim, M. K., Han, J., Jung, H.-Y., Kim, A., Jun, T. J., & Kim, Y. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf036 · Cited by 10
Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke
Jung, Y. H., Song, T. J., Kim, J., Park, H.-K., Han, S. W., Kim, Y. D., Park, J.-H., Cha, J., Park, H. Y., Sohn, S., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.0398 · Cited by 10
Association of gut microbiota and immunometabolic profiles with ischemic stroke severity
Pilon, C. R. S., Guadagnini, D., Assalin, H. B., Magro, D. O., Oliveira, E. S., Alborghetti, M. R., Sforça, M. L., Rocco, S. A., Sartoratto, A., Santos, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-97432-2 · Cited by 11
Kwok, G. Y. R., Chen, R. W. R., Leow, T. A., Kok, C. H. P., Yeong, N., Teo, Y. H., Low, C. E., Wright, S. L., Fink, J., Sharma, V. K., et al. (2025) · International Journal of Stroke · doi:10.1177/17474930251340799 · Cited by 10
Wang, C.-S., Wu, Y.-H., Fu, Y., Jan, S., Lin, M., Hsu, C., & Chen, P. (2025) · European Stroke Journal · doi:10.1177/23969873251341764 · Cited by 10
Zhao, L., Li, T., Dang, M., Li, Y., Lu, J., Lu, Z., Chen, Z., Huang, Q., Chen, Y., Yang, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202411873 · Cited by 11
Acute Ischaemic Stroke Incidence after Coronavirus Vaccine in Indonesia: Case Series
Hidayat, R., Diafiri, D., Zairinal, R. A., Arifin, G. R., Azzahroh, F., Widjaya, N., Fani, D. N., Mesiano, T., Kurniawan, M., Rasyid, A., et al. (2021) · Current Neurovascular Research · doi:10.2174/1567202618666210927095613 · Cited by 10
Under Treatment of High-Risk TIA Patients with Clopidogrel-Aspirin in the Emergency Setting
Lendaris, A. R., Lessen, S., Cheng, N. T., Friedman, B. W., Esenwa, C. C., Labovitz, D., Prabhakaran, S., Lipton, R. B., & Liberman, A. L. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.106145 · Cited by 10
Carlsson, C. M. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001132 · Cited by 10
Al‐Abdouh, A., Abusnina, W. A., Mhanna, M., Radideh, Q., Alzu’bi, H., Rmilah, A. A. A., Jabri, A., Barbarawi, M., Obeidat, K., Alabduh, T., et al. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101292 · Cited by 10
Iluţ, S., Pîrlog, B. O., Pîrlog, R., Nutu, A. M., Văcăraș, V., & Armean, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810221 · Cited by 11
Rana, A., Yu, S., Reid-Herrera, S., Kamen, S. E., Hunter, K. M., Shaikh, H. A., Jovin, T. G., Thon, O. R., Patel, P., Siegler, J. E., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.939215 · Cited by 10
Mansutti, I., Saiani, L., Cargnelutti, D., Petrucco, S., Giannina, V., Domenico, C. D., Passadore, P., & Palese, A. (2022) · Journal of Vascular Nursing · doi:10.1016/j.jvn.2022.09.003 · Cited by 11
Ecological model of health behaviour of hypertensive stroke patients at the end of recovery period
Zhang, L., Wang, M., Deng, C., Lin, M., Chen, J., & Wan, L. (2022) · Journal of Clinical Nursing · doi:10.1111/jocn.16566 · Cited by 10
Murray, N. M., Marshall, S., Hoesch, R. E., Hobbs, K. S., Smith, S. M., Roller, D., Thomas, K. P., Meier, K., & Püttgen, H. A. (2022) · Neurocritical Care · doi:10.1007/s12028-022-01632-x · Cited by 10
Self-citationBundled Approach to Improve Inpatient Stroke Recognition and Time to Treatment
Drollinger, L., & Prasun, M. A. (2022) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0000000000000685 · Cited by 10
Rasyid, A., Pemila, U., Aisah, S. N., Harris, S., Wiyarta, E., & Fisher, M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1177083 · Cited by 10
Amarenco, P., Lavallée, P. C., Kim, J. S., Labreuche, J., Charles, H., Giroud, M., Lee, B., Mahagne, M., Meseguer, E., Nighoghossian, N., et al. (2023) · Stroke · doi:10.1161/strokeaha.123.042621 · Cited by 10
Management and Prognosis of Acute Stroke in Atrial Fibrillation
Hindsholm, M. F., Damgaard, D., Gurol, M. E., Gaist, D., & Simonsen, C. Z. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175752 · Cited by 11
Statin Therapy for Secondary Prevention in Ischemic Stroke Patients With Cerebral Microbleeds
Prats‐Sánchez, L., Camps‐Renom, P., Nash, P. S., Wilson, D., Ambler, G., Best, J. G., Guasch‐Jiménez, M., Ramos‐Pachón, A., Domeño, A. M., Gil, Á. L., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209173 · Cited by 10
Projections of Endovascular Therapy–Eligible Patients With Stroke for the US Population
Mistry, E. A., Khoury, J. C., Kleindorfer, D., D, B. M. K. M., Alwell, K., Jasne, A. S., Ferioli, S., Rosa, F. D. L. R. L., Coleman, E. R., Demel, S. L., et al. (2024) · Stroke · doi:10.1161/strokeaha.123.045766 · Cited by 10
Self-citationGuan, L., Han, S., Johnston, S. C., Bath, P. M., Amarenco, P., Yang, Y., Wang, T., Jing, J., Wang, C., Gao, Y., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209845 · Cited by 10
Pathogenetic mechanisms of ischemic stroke: from verification to secondary prevention
Kulesh, A. A., Демин, Д. А., & Vinogradov, O. I. (2021) · Consilium Medicum · doi:10.26442/20751753.2021.11.201153 · Cited by 11
Doheim, M. F., Al‐Bayati, A. R., Bhatt, N., Lang, M. J., Starr, M. T., Rocha, M., Gross, B. A., & Nogueira, R. G. (2023) · Interventional Neuroradiology · doi:10.1177/15910199231206044 · Cited by 10
Kent, D. M., Saver, J. L., Kasner, S. E., Nelson, J., Wang, A. Y.-D., Bannuru, R. R., Carroll, J., Châtellier, G., Dérumeaux, G., Furlan, A. J., et al. (2023) · doi:10.25302/04.2023.rs.scope2019001 · Cited by 10
Jokubaitis, M., Mineikytė, R., Kryžauskaitė, L., Gumbienė, L., Kaplerienė, L., Andruškevičius, S., & Ryliškienė, K. (2022) · Medicina · doi:10.3390/medicina58081056 · Cited by 9
Pharmacological treatment in patients with aortic dissection
Smedberg, C., Hultgren, R., Leander, K., & Steuer, J. (2022) · Open Heart · doi:10.1136/openhrt-2022-002082 · Cited by 10
Amanzonwé, E. R., Kossi, O., Noukpo, S. I., Adoukonou, T., Hansen, D., Triccas, L. T., & Feys, P. (2023) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2023.107353 · Cited by 9
Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment
Xu, Y., Hu, Y., Wu, G., Niu, L., Fang, C., Li, Y., Jiang, L., Yuan, C., & Huang, M. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128618 · Cited by 9
Guo, Z., Zhang, K., Zhang, P., Qu, Y., Abuduxukuer, R., Nguyen, T. N., Chen, D., & Yang, Y. (2024) · European Stroke Journal · doi:10.1177/23969873231225069 · Cited by 9
Self-citationDunn, L. E., Wang, Y., Kass‐Hout, T., & Chiu, D. (2024) · Stroke · doi:10.1161/strokeaha.123.043632 · Cited by 10
Lee, M., Lee, B., Yu, K., Oh, M. S., Kim, B. J., Kim, J. Y., Kang, J., Lee, K., Kim, D. Y., Park, J., et al. (2024) · Stroke · doi:10.1161/strokeaha.123.044487 · Cited by 9
Lengyel, B., Magyar-Stang, R., Pál, H., Debreczeni, R., Sándor, Á. D., Székely, A. D., Gyürki, D., Csippa, B., István, L., Kovács, I., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13092487 · Cited by 9
Type 2 diabetes mellitus in patients with ischemic stroke – A nationwide study
Hastrup, S., Hedegaard, J. N., Andersen, G., Rungby, J., & Johnsen, S. P. (2024) · Diabetic Medicine · doi:10.1111/dme.15337 · Cited by 11
Machine Learning-Based Etiologic Subtyping of Ischemic Stroke Using Circulating Exosomal microRNAs
Bang, J. H., Kim, E. H., Kim, H. J., Chung, J., Seo, W., Kim, G., Lee, D., Kim, H., & Bang, O. Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126761 · Cited by 10
Apple, S. J., Parker, M., Flomenbaum, D. E., Rosenbaum, S. M., Borck, J., Choppa, A., Borkowski, P., Satish, V., Alhuarrat, M. A. D., Fisher, J. D., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.07.004 · Cited by 9
Slotabec, L. A., Seale, B. C., Wang, H., Wen, C., Filho, F., Rouhi, N., Adenawoola, M. I., & Li, J. (2024) · The FASEB Journal · doi:10.1096/fj.202401128r · Cited by 9
Fu, C.-H., Chen, C., Lin, Y., Lee, C., Tsai, L., Tang, S., Shun, C., & Jeng, J. (2024) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2024-022033 · Cited by 9
Lun, F., Palaiodimou, L., Katsanos, A. H., Tsivgoulis, G. K., & Turc, G. (2024) · European Stroke Journal · doi:10.1177/23969873241293323 · Cited by 9
Ren, H., Song, H., Liu, J., Cui, S., Gong, M., & Li, Y. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.09.052 · Cited by 9
Zhang, Y., Wu, J., Liu, Y., & Liu, Y. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.10.030 · Cited by 9
Rajesh, K., Spring, K. J., Smokovski, I., Upmanyue, V., Mehndiratta, M. M., Strippoli, G. F., Beran, R. G., & Bhaskar, S. M. M. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02556-w · Cited by 11
Yao, C., Qin, Y., Yan, X., Zhao, Z., Wang, B., Bai, Y., Zhang, T., & Hou, Y. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04385-x · Cited by 9
Association of physical activity, sedentary behavior and stroke in older adults
Bai, L., Wen, Z., Yan, X., Wu, S., & Chen, J. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1484765 · Cited by 9
Hoh, B. L., Martin, R. H., Yeatts, S. D., Turan, T. N., Boyette, R., McLaren, S., Butler, L., Peters, K., Smith, J. L., Cavallari, L. H., et al. (2024) · International Journal of Stroke · doi:10.1177/17474930241313301 · Cited by 9
Self-citationTunehag, K. R., Pearce, A. F., Fox, L. P., Stouffer, G. A., Solander, S. Y., & Lee, C. R. (2025) · Clinical and Translational Science · doi:10.1111/cts.70131 · Cited by 10
High-resolution magnetic resonance vessel wall imaging in extracranial cervical artery dissection
Shao, S., & Wang, G. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1536581 · Cited by 9
Molecular heterogeneity in human stroke – What can we learn from the peripheral blood transcriptome?
Stamova, B. S., Knepp, B., & Rodríguez, F. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251322598 · Cited by 11
Siegler, J. E., Badillo‐Goicoechea, E., Penckofer, M., Eklund, K., Yaghi, S. R., Stretz, C., Lineback, C. M., Stamm, B. J., Peter, S., D’Souza, M., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213876 · Cited by 9
Self-citationWang, W., Pang, M., Zhang, Y., Hou, S., Xia, Y., Shi, Y., Zhang, X., & Wang, Y. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05253-1 · Cited by 9
Role and Mechanism of Microglia in White Matter Injury Recovery in Ischemic Stroke
Guo, Y., Shang, Y., Yao, J., & Bi, X. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70226 · Cited by 12
Rai, P., Bathla, G., Praveen, N., Gopikonda, S. S., Chen, H. A., Salim, H. A., Azzam, A. Y., Essibayi, M. A., Altschul, D., Dmytriw, A. A., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13470-w · Cited by 9
Proposal for the Ischemic Stroke Phenotyping System 2025: ISPS25
Yaghi, S. R., Johansen, M. C., Ghannam, M., Kasner, S. E., Singh, N., Sposato, L. A., Siegler, J. E., Sur, N. B., Khan, F. H., Kamel, H., et al. (2025) · Stroke · doi:10.1161/strokeaha.125.051169 · Cited by 9
Self-citationInpatient Management of Acute Stroke and Transient Ischemic Attack
Patrick, L. M., & Halabi, C. (2021) · Neurologic Clinics · doi:10.1016/j.ncl.2021.08.003 · Cited by 9
Quality of acute ischemic stroke care at a tertiary Hospital in Ghana
Kumi, F., Bugri, A. A., Adjei, S., Duorinaa, E., & Aidoo, M. (2022) · BMC Neurology · doi:10.1186/s12883-021-02542-9 · Cited by 9
Awosika, O. O., Chan, D., Sucharew, H. J., Boyne, P., Bhattacharya, A., Dunning, K. K., & D, B. M. K. M. (2022) · Brain Sciences · doi:10.3390/brainsci12020133 · Cited by 9
Metadata
- Authors
- Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., Lennon, O., Meschia, J. F., Nguyen, T. N., Pollak, P. M., Santangeli, P., Sharrief, A. Z., Smith, S. C., Turan, T. N., & Williams, L. S.
- ORCID
- Venue
- Stroke
- Published
- 2021-07
- Volume
- 52
- Issue
- 7
- Pages
- e364-e467
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W3164908038
- Semantic Scholar
- 18bb9d19bdfe54d5d1289c0a74fbcb410e3e1b6d
- Cited by
- 3,237
- References
- 892
- Citations by year
- 2026: 653 · 2025: 670 · 2024: 778 · 2023: 618 · 2022: 432 · 2021: 82
- FWCI
- 72.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-06-28)
- Open access
- bronze
- doi.org
- Locations
- Stroke (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- Congress of Neurological Surgeons
- Topics
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- secondary stroke prevention, stroke recurrence, transient ischemic attack, stroke risk factors
- MeSH terms
- Clinical Decision-Making, American Heart Association, Ischemic Attack, Transient, Humans, United States, Practice Guidelines as Topic, Stroke, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
